Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Novartis 4Q

In the quarter, Pharmaceutical sales were up 21% to $7.8 billion.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis 4Q

4Q Revenues: $12.9 billion (+8%)

4Q Earnings: $2.3 billion (+54%)

FY Revenues: $44.3 billion (+7%)

FY Earnings: $8.5 billion (+4%)

Comments: In the quarter, Pharmaceutical sales were up 21% to $7.8 billion. Vaccines and Diagnostics revenue was up 182% to $1.4 billion and included $1.0 billion of H1N1 pandemic vaccine and adjuvant sales. Sandoz (generic) revenue was up 19% to $2.1 billion. Consumer Health revenues were up 20% to $1.6 billion. For the year, Pharmaceutical sales were up 8% to $28.5 billion, Vaccines and Diagnostics sales were up 38% to $2.4 billion, Sandoz sales were $7.5 billion (-1%) and Consumer Health sales were flat at $5.8 billion. Top-performing regions included Europe ($18.4 billion, +10% lc) and the U.S. ($14.3 billion, +11% lc) as well as the top six emerging markets ($4.0 billion, +17% lc) of Brazil, China, India, Russia, South Korea and Turkey.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters